phone icon  Int'l : +1-503-894-6022
0
Shopping Cart is Empty..
$ 0

World Lung Cancer Therapeutics Market

- Opportunities and Forecasts, 2014 -2020
 Report Code: LI 16351
 Pages: NA
 Format: PDF Exel CD_rom
pub_n Upcoming Date: May 2016
tab_nTables: NA
aut_nAuthor(s):

Lung cancer is a malignant lung carcinoma that is characterized by abnormal cell growth in lung tissue. As the tumor grows in size, it decreases the lungs’ ability to provide oxygen to bloodstream. The primary lung carcinomas originate from epithelial cells and classified as non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Major symptoms of lung cancer include coughing, body mucus, wheezing, shortness of breath, chest pain and weight loss. Lung cancer has high mortality rate all over the globe and the foremost reason includes cigarette smoking. Treatments of lung cancer include chemotherapy and radiation therapy. This report provides in-depth discussion on global lung cancer therapeutics market and includes past and current trends with future forecast up to 2020. The report provides threats and opportunities for new and existing companies running the business in this market. The report is informative towards geographical segmentation and identifies profitable areas.

Global lung cancer therapeutics market shows promising CAGR due to increasing population of lung cancer and it is expected that trend would continue with the same momentum. Advanced stages of lung cancer still show high unmet need for diagnosis and treatment. The potential drivers for lung cancer therapeutic market include tobacco smoking (including passive smoke), aged population and lifestyle factors. Additionally, innovative and targeted drug delivery to lung is found to be a major driver for the growth of this market. However, high unmet need for diagnosis, availability of large number of generic forms of major drugs and limited treatment options are the critical restrains to the global lung cancer therapeutics market. Chemotherapy and radiation therapy poses bigger challenge of adverse effect. Hence, big players in this market have to focus on innovative therapies and safer therapeutics. 

Global Lung Cancer Therapeutics Market by Therapeutics

The global lung cancer therapeutics market is segmented by therapy into five broad categories, namely Chemotherapy, Targeted therapy and Pipeline drugs, Surgery and Radiotherapy. NSCLC contributes for high prevalence than SCLC. Avastin by Roche was the blockbuster drug for the past few years that accounted for major percentage of the total sale. Other top brands of therapeutics include Gemzar, Taxotere and Tarceva and used for NSCLC. For SCLC treatment, ifosfamide or etoposide is combined with platinum analog and forms standard chemotherapeutic regimen. Many a times, Radiotherapy in combination with chemotherapy, is used as better option before surgery to increase the effectiveness of the treatment. Key Challenge in successful pipeline therapy includes its integration with existing therapy or its superiority over existing therapy.

Global Lung Cancer Therapeutics Market by Geography

Geographically, global lung cancer therapeutics market is segmented into North America, Europe, Asia-Pacific and LAMEA. North America and Europe are the leading global lung cancer therapeutic markets due to high incidences and large pool of aging population. Additionally, lifestyle standard with high smoking habits leads to a large pool of lung carcinoma population. Asia-Pacific is the emerging market, where India has shown high incidence in past few years, whereas, LAMEA contributes to smaller volume as compared to North America and Europe.

Competitive Landscape

The leading companies in global lung cancer therapeutics market include Roche, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly and Company, Pfizer, and Agennix AG. Currently, Roche, Agennix AG and Pfizer are ruling the market for global lung cancer therapeutics and expected to capture half of the market share during the forecast period. Decline in sales value of AstraZeneca was attributed to large number of generic drugs entering the market. Eli Lilly has achieved a top position next to AstraZeneca and Sanofi-Aventis due to exceptional sales performance of its key product Alimta.  

High Level Analysis

The study identifies the potential market drivers, challenges and trends. Competitive landscape section provides explicit information of the big players ruling the global lung cancer therapeutics market, their operating strategies, new launches, pipeline therapies and clinical trials. Porter’s five forces analysis has been used to determine the attractiveness of global lung cancer therapeutics market. Chemotherapy and radiation therapy shows large number of side effects and many a times need to be followed by surgery. Hence, constant demand for safe and efficacious therapeutics and improved technology is responsible to increase the bargaining power of suppliers. Large number of generic drugs is entering the market and therefore, the threat of substitute products tends to be high. To fulfill the demand for safe and effective drug therapy, many companies are putting their effort to pipeline research. Thus, it led to commercialization of large number of products and due to which rivalry is intense among participants.

KEY BENEFITS

  • This report offers the following benefits in particular:
  • Comprehensive coverage of global lung cancer therapeutics market along with disease overview, market trends, drivers and restraints
  • Through attention is given to leading company portfolios, pipeline research, new launches and competitive landscape of top players
  • Explicit information on current clinical trials and R&D activities, would be beneficial to understand the future market trends  
  • Insightful analysis of different segments helps to recognize and capitalize future opportunities within global lung cancer therapeutics market

KEY DELIVERABLES

The global lung cancer therapeutics market is segmented into two major categories such as, therapeutics and geography. 

BY THERAPY

  • Chemotherapy
    • Taxotere
    • Hycamtin
    • Navelbine
    • Gemzar
    • Alimta
  • Targeted therapy
    • Tarceva
    • Iressa
    • Avastin
  • Pipeline drugs
    • Talactoferrin 
    • Dacomitinib
    • Afatinib
    • Erbitux
    • ARQ 197
    • Ramucirumab
  • Surgery
    • Pneumectomy (Removal of whole lung)
    • Bilobectomy (Removal both lobes)
    • Lobectomy (removal of one lobe)
  • Radiotherapy

BY GEOGRAPHY

  • North America
  • Europe
  • Asia-Pacific
  • LAMEA
Let us know more about your research need and we will customize an offer exclusively for you!
*
*
*
*
*
*
*
security
*

With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
SINGLE USER
GROUP LICENSE
SITE LICENSE
GLOBAL LICENSE
$3951
$4660
$6432
$9345
LICENSE INFO
Users/Sharing
Restricted to one authorized user

Limited to 5 authorized users

Up to 25 users


unlimited within company / enterprise
Copy/Paste
Allowed up to 20% of the content
Allowed up to 25% of the content
Allowed up to 50% of the content
allowed 100%

Printing
One print only

Five Prints

Unlimited for internal use
Unlimited for internal use
Delivery Formats
ADDED BENIFITS
20% Free customization (Pre-sale)
16 Analyst hour support (Post Sale)
40 Analyst hour support (Post Sale)
160 hours of mini-consult
Free quarterly industry update
Free report on update (within 180 days)
MULTIPLE PURCHASE
Complimentary report with 2 reports
Complimentary report with 3 reports
Subscription Model
Have questions ?
connect
Need to add more ?
request

Single User $4515
$3951
Group User $5325
$4660
Site User $7350
$6432
Global User $10680
$9345
First time buyer ?
Check offers and discount
on this report
REQUEST QUOTE
Need More Information
phone_n +1-503-894-6022

Help AMR help@alliedmarketresearch.com
Or
Send Enquiry
WHY ALLIED MARKET RESEARCH?
Infallible Methodology
To ensure high level data integrity, accurate analysis and impeccable forecasts
ANALYST SUPPORT
For complete satisfaction
CUSTOMIZATION
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET
Targeted market view to eliminate redundant information to provide valued information and save time of the reader
RECENTLY VIEWED REPORTS
get_n
SIMILAR MARKET REPORTS
  • ...
    Enteral feeding devices are used to deliver nutrition or medications directly into the stomach or intestine. These devices are commonly used to feed the specialized diet in elderly or bedridden patients suffering from chronic ailments such as neurological disorders, cancer, gastro intestinal and inherited metabolic diseases.
    Aug 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Imaging modalities emerged as a preferred option for the clinical industry, especially in preclinical studies. Many of the imaging technologies have been translated into micro level tools that include micro MRI, micro CT and micro PET. Apart from these technologies, micro ultrasound imaging, micro-magnetic resonance imaging (MRI), optical Imaging such as bioluminescence and fluorescence imaging, and multimodal imaging technologies have gained traction in the market.
    Feb 2015 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Traditional wound care & closure and advanced wound care & closure products are used to treat acute and chronic wounds. Chronic wounds are hard to heal wounds, which take substantial time to heal and are expensive to treat. Advanced wound care & closure products are emerging as a standard solution for treating chronic wounds.
    Jul 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
  • ...
    Catheters are thin tubes made up of medical grade material such as plastic, silicon rubber, PVC and nylon that are inserted in the patient’s body for therapeutic and diagnostic purposes. Catheterization is a primary co-procedure along with varied other medical procedures such as angioplasty, cardiac electrophysiology, and neurosurgery among others. They are the vital component in several surgical procedures.
    Nov 2014 | Price: $4515(SU) €0(SU) £0(SU) | View Details >>
ON DEMAND REPORTS
  • ...
    Magnetic Resonance Imaging (MRI) is a technique used in radiology to capture images of physiological processes in body. Closed MRI system is a tube-like tunnel with high field strength used to obtain greater resolution and thinner slices. It is helpful to study smaller parts of body. It scans patients faster than other MRI systems. Closed MRI systems use magnetic field and radio waves that screen and diagnose various diseases, such as multiple sclerosis (MS), cartilage degeneration in the knee, breast cancer, dementia, prostate cancer, spinal tuberculosis, and others.
    May 2016 | View Details >>
  • ...
    A fluid Management and Visualization system is used to balance body fluid in order to prevent complications associated with an undesired fluid level. It is also used for the early diagnosis of critical medical conditions. Fluid management systems perform functions such as fluid irrigation, fluid warming, fluid filtration, fluid deficit monitoring etc. Growing inclination towards minimally invasive surgeries and technological advancements in fluid management and visualization system products are expected to supplement the market growth.
    May 2016 | View Details >>
  • ...
    Implantable drug delivery devices are the medical devices, which enable site specific drug administration. It also helps in minimizing the doses of drug in order to reduce potential side effects. These devices facilitate sustained release of a therapeutic agent. These implantable devices are gaining edge over conventional oral or parenteral dosage forms due to site specific and sustained release therapeutic action of implantable devices, which further minimize the side-effects associated with the drug.
    May 2016 | View Details >>
  • ...
    Exocrine pancreatic insufficiency (EPI) is an inability of proper digestion of food owing to insufficient levels of digestive enzymes from pancreas. EPI is commonly found in humans affected with Shwachman-Diamond Syndrome and cystic fibrosis. EPI is triggered by the progressive loss of pancreatic cells, which generates the digestive enzymes.
    May 2016 | View Details >>